Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals

The Pharmacogenomics Journal volume 9, pages 327–332 (2009)Cite this article

Abstract

Cytochrome P450 2C9 (CYP2C9) enzymes metabolize warfarin and arachidonic acid. We hypothesized that the CYP2C9*2 (rs.1799853) and CYP2C9*3 (rs.1057910) polymorphisms with decreased enzyme activity affect risk of subclinical atherosclerosis (reduced ankle brachial index and increased C-reactive protein), ischemic vascular diseases (ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease and ischemic stroke) and death after an ischemic heart disease diagnosis. We genotyped the Copenhagen City Heart Study, a prospective study including 10 398 participants with 30–32 years of follow-up; the Copenhagen General Population Study, a cross-sectional study including 21 629 participants; and the Copenhagen Ischemic Heart Disease Study, a case–control study including 5082 cases and 14 904 controls. CYP2C9 carriers versus noncarriers did not associate with subclinical atherosclerosis. Furthermore, the odds/hazard ratios for ischemic vascular disease did not differ from 1.0 for CYP2C9 carriers versus noncarriers. Finally, we found no altered risk of early death after a diagnosis of ischemic heart disease. For all end points, we could exclude even minor changes in risk of disease with 90% power. In conclusion, in three independent studies totaling more than 52 000 individuals, we found no association between CYP2C9*2 and CYP2C9*3 polymorphisms and risk of subclinical atherosclerosis, ischemic vascular disease or death after ischemic heart disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Rifkind AB, Lee C, Chang TK, Waxman DJ . Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320: 380–389.

    Article  CAS  PubMed  Google Scholar 

  2. Williams PA, Cosme J, Ward A, Angove HC, Matak VD, Jhoti H . Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464–468.

    Article  CAS  PubMed  Google Scholar 

  3. Aithal GP, Day CP, Kesteven PJ, Daly AK . Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717–719.

    Article  CAS  PubMed  Google Scholar 

  4. US Food and Drug Administration. 2009. Ref Type: Internet Communication. www.fda.gov/

  5. Theken KN, Lee CR . Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 2007; 8: 1369–1383.

    Article  CAS  PubMed  Google Scholar 

  6. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276–1279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Larsen BT, Gutterman DD, Hatoum OA . Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest 2006; 36: 293–300.

    Article  CAS  PubMed  Google Scholar 

  8. Spiecker M, Liao JK . Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005; 433: 413–420.

    Article  CAS  PubMed  Google Scholar 

  9. Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM . Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009; 46: 67–74.

    Article  CAS  PubMed  Google Scholar 

  10. EnayetAllah AE, French RA, Thibodeau MS, Grant DF . Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52: 447–454.

    Article  CAS  PubMed  Google Scholar 

  11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.

    Article  CAS  PubMed  Google Scholar 

  12. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.

    Article  CAS  PubMed  Google Scholar 

  13. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG . Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23: 620–626.

    Article  CAS  PubMed  Google Scholar 

  14. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299: 2524–2532.

    Article  CAS  PubMed  Google Scholar 

  15. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG . Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897–1908.

    Article  CAS  PubMed  Google Scholar 

  16. Eldrup N, Sillesen H, Prescott E, Nordestgaard BG . Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. Eur Heart J 2006; 27: 316–322.

    Article  CAS  PubMed  Google Scholar 

  17. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG . Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142–2152.

    Article  CAS  PubMed  Google Scholar 

  18. Daikh BE, Lasker JM, Raucy JL, Koop DR . Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 1994; 271: 1427–1433.

    CAS  PubMed  Google Scholar 

  19. Funk M, Endler G, Freitag R, Wojta J, Huber K, Mannhalter C et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 2004; 50: 2395–2398.

    Article  CAS  PubMed  Google Scholar 

  20. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13: 715–720.

    Article  CAS  PubMed  Google Scholar 

  21. Ercan B, Ayaz L, Cicek D, Tamer L . Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct 2008; 26: 309–313.

    Article  CAS  PubMed  Google Scholar 

  22. Funk M, Freitag R, Endler G, Lalouschek W, Lang W, Mannhalter C et al. Influence of cytochrome P450 2C9*2 and 2C9*3 variants on the risk of ischemic stroke: a cross-sectional case–control study. Clin Chem 2005; 51: 1716–1718.

    Article  CAS  PubMed  Google Scholar 

  23. Marciante KD, Totah RA, Heckbert SR, Smith NL, Lemaitre RN, Lumley T et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18: 535–543.

    Article  CAS  PubMed  Google Scholar 

  24. Morgan TM, Krumholz HM, Lifton RP, Spertus JA . Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297: 1551–1561.

    Article  CAS  PubMed  Google Scholar 

  25. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM et al. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics 2007; 17: 473–479.

    Article  CAS  PubMed  Google Scholar 

  26. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F . Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628–631.

    Article  CAS  PubMed  Google Scholar 

  27. Fleming I . Cytochrome p450 and vascular homeostasis. Circ Res 2001; 89: 753–762.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Danish Heart Foundation, the Novo Nordisk Foundation and the Danish Medical Research Council.

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark

    D Kaur-Knudsen, S E Bojesen & B G Nordestgaard

  2. The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark

    D Kaur-Knudsen, S E Bojesen & B G Nordestgaard

  3. The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark

    S E Bojesen & B G Nordestgaard

  4. Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

    D Kaur-Knudsen, S E Bojesen & B G Nordestgaard

Authors
  1. D Kaur-Knudsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S E Bojesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B G Nordestgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B G Nordestgaard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaur-Knudsen, D., Bojesen, S. & Nordestgaard, B. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals. Pharmacogenomics J 9, 327–332 (2009). https://doi.org/10.1038/tpj.2009.34

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2009.34

Keywords

This article is cited by

Search

Advanced search

Quick links